Nature Immunology:精氨酸酶调节ILC2免疫活性

2016-05-30 佚名 生物谷

先天淋巴细胞(innate lymphoid cell, ILC)免疫系统重要的组成部分,它们参与调节免疫反应,炎症,代谢稳态以及多种器官组织的修复(包括肝脏,肺脏,皮肤以及脂肪组织)。II型ILC是ILC中比例最高的一个亚群(ILC2),主要聚集在肺部,是II型炎症反应的关键起始元件。然而,调节ILC功能的细胞内部分子机制至今研究的仍不清楚。 精氨酸酶I(Arg1)能够催化L-精氨酸生成尿素

先天淋巴细胞(innate lymphoid cell, ILC)免疫系统重要的组成部分,它们参与调节免疫反应,炎症,代谢稳态以及多种器官组织的修复(包括肝脏,肺脏,皮肤以及脂肪组织)。II型ILC是ILC中比例最高的一个亚群(ILC2),主要聚集在肺部,是II型炎症反应的关键起始元件。然而,调节ILC功能的细胞内部分子机制至今研究的仍不清楚。

精氨酸酶I(Arg1)能够催化L-精氨酸生成尿素以及鸟氨酸,进而促进胶原蛋白的合成以及细胞的增殖。此前研究发现,arg1除了能够调节尿素代谢以外,它在免疫细胞中也发挥着至关重要的作用,尤其是II型炎症反应。最近,来自抗癌尔大学微生物学与免疫学系的David Artis课题组在《nature immunology》发表文章,揭示了Arg1在调节ILC2以及II型炎症反应中的作用。

此前已经有文章报道,在成熟的ILC2中有arg1的表达,但是是否arg1同样在其前体细胞中有表达仍不清楚。对此,研究者们提取了arg1-YFP报告基因小鼠不同分化阶段的ILC2前体细胞进行流式检测。结果显示,在HSC(hematopoietic stem cells),CLP(common lymphoid progenitors)以及CHILP(common innate lymphoid progenitor)均没有arg1的表达,这一结果表明arg1表达是在ILC2分化到已经阶段才出现的现象。之后,作者希望了解arg1在ILC2中的表达上调是否会受到外界环境的影响。通过比较不同组织的ILC2,作者发现arg1在不同组织的ILC2中均能够稳定地表达。

由于此前研究发现Arg1在调节肺部免疫稳态中具有重要的作用,作者希望了解肺脏中哪一类细胞大量表达这一蛋白。通过分析所有肺脏中表达Arg1(即YFP阳性)的细胞,作者发现其中大部分是ILC2。

进一步,为了研究是否Arg1调节了ILC2的炎症反应活性,作者构建了一个小鼠呼吸道急性过敏炎症反应模型:通过向鼻腔中滴灌木瓜蛋白酶,能够引发Arg1的表达,同时肺脏中出现了大量的ILC2。进一步的细胞分析也表明大部分表达Arg1的细胞为ILC2。同时,作者对患有慢性阻塞性肺炎的患者的肺脏样本进行了上述分析,得到了相似的结果。

之后,作者人为地敲除了小鼠ILC2中的Arg1基因。通过炎症反应试验,作者发现这种小鼠呼吸道炎症反应的强度出现了明显的下降。进一步,作者利用小鼠慢性炎症反应模型进行试验,发现在缺失了Arg1之后,ILC2的反应受到了明显的阻碍。同时,作者发现只有ILC2细胞中的Arg1能够影响肺部的炎症反应,除此之外,髓系来源细胞内部的Arg1并不能对肺部炎症反应产生影响。

接下来,作者发现Arg1的缺失能够导致ILC2的增殖能力受到影响,而细胞的凋亡则没有明显改变。这能够导致在肺部炎症反应过程中ILC2的数量比例产生差异。最后,作者发现Arg1参与了ILC2细胞内部糖酵解的活动,Arg1酶活性的破坏能够引起ILC2细胞内部代谢的紊乱,这也许是导致其增值能力下降的原因。

原始出处

Laurel A Monticelli, Michael D Buck, Anne-Laure Flamar, Steven A Saenz, Elia D Tait Wojno, Naomi A Yudanin, Lisa C Osborne, Matthew R Hepworth, Sara V Tran, Hans-Reimer Rodewald, Hardik Shah, Justin R Cross4, Joshua M Diamond, Edward Cantu, Jason D Christie, Erika L Pearce & David ArtisArginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation Nature Immunology.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928745, encodeId=bc451928e4527, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Apr 03 07:34:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881080, encodeId=39af188108046, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 08:34:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87700, encodeId=6a458e700ad, content=很好有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:40:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87679, encodeId=e73c8e67927, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:18:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928745, encodeId=bc451928e4527, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Apr 03 07:34:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881080, encodeId=39af188108046, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 08:34:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87700, encodeId=6a458e700ad, content=很好有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:40:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87679, encodeId=e73c8e67927, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:18:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-06-24 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928745, encodeId=bc451928e4527, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Apr 03 07:34:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881080, encodeId=39af188108046, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 08:34:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87700, encodeId=6a458e700ad, content=很好有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:40:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87679, encodeId=e73c8e67927, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:18:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-31 忠诚向上

    很好有用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1928745, encodeId=bc451928e4527, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Mon Apr 03 07:34:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881080, encodeId=39af188108046, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 24 08:34:00 CST 2016, time=2016-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87700, encodeId=6a458e700ad, content=很好有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue May 31 05:40:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87679, encodeId=e73c8e67927, content=努力学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Mon May 30 23:18:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-30 足球疯子

    努力学习中

    0